Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 3:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Age 18-64 Years Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults

NCT02768805
View directory record Official record
Conditions
Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions
15 µg/strain of Quadrivalent VLP Vaccine, 30 µg/strain of Quadrivalent VLP Vaccine, 15 µg/strain of the licensed quadrivalent vaccine
Biological
Lead sponsor
Medicago
Industry
Eligibility
18 Years to 64 Years
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
3
States / cities
Hollywood, Florida • South Miami, Florida • Endwell, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Jun 10, 2026, 3:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Adults Aged >= 18 and <= 64, Plus Revaccination

NCT00889889
View directory record Official record
Conditions
Influenza
Interventions
Cell-Derived Trivalent Subunit Influenza Vaccine, Placebo
Biological
Lead sponsor
Abbott Biologicals
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
15
States / cities
Jacksonville, Florida • Pembroke Pines, Florida • South Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Jun 10, 2026, 3:28 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults

NCT00772109
View directory record Official record
Conditions
Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions
Influenza Virus Vaccine USP Trivalent Types A and B
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
4,292 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
46
States / cities
Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Jun 10, 2026, 3:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age

NCT01659086
View directory record Official record
Conditions
Influenza
Interventions
Investigational H9N2 vaccine GSK2654911A, Investigational H9N2 vaccine GSK2654909A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
422 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
3
States / cities
Miami, Florida • Edison, New Jersey • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2018 · Synced Jun 10, 2026, 3:28 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Comparison of Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years

NCT05514002
View directory record Official record
Conditions
Influenza, Human
Interventions
Fluzone Quadrivalent, Flublok Quadrivalent
Biological
Lead sponsor
Fatimah Dawood
Federal
Eligibility
18 Years to 64 Years
Enrollment
3,988 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
4
States / cities
Tucson, Arizona • Tallahassee, Florida • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Jun 10, 2026, 3:28 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults

NCT05266456
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
24 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
835 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
13
States / cities
Hollywood, Florida • Sunrise, Florida • Savannah, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Jun 10, 2026, 3:28 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults

NCT05975840
View directory record Official record
Conditions
Influenza, Human
Interventions
FLU Q-PAN H5N8 375_B, FLU Q-PAN H5N8 375_A, FLU Q-PAN H5N8 750_B, FLU Q-PAN H5N8 750_A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
20
States / cities
Anniston, Alabama • Mobile, Alabama • Tempe, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Jun 10, 2026, 3:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM

NCT01011049
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine USP Trivalent Types A and B
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
44
States / cities
Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Jun 10, 2026, 3:28 AM EDT
Completed Phase 4 Interventional

Randomized Influenza Vaccine Evaluation of Immune Response

NCT03598439
View directory record Official record
Conditions
Influenza
Interventions
Standard IIV4, Recombinant, Cell-culture
Biological
Lead sponsor
Marshfield Clinic Research Foundation
Other
Eligibility
18 Years to 64 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Jun 10, 2026, 3:28 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP

NCT03722589
View directory record Official record
Conditions
Influenza
Interventions
Flublok, Flucelvax, Fluarix, Fluzone, Fluzone High-Dose
Biological
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 65 Years
Enrollment
944 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Portland, Oregon • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2024 · Synced Jun 10, 2026, 3:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older

NCT04789577
View directory record Official record
Conditions
Influenza, Human
Interventions
FLU-Q-PAN H7N9 Formulation 1, FLU-Q-PAN H7N9 Formulation 2, FLU-Q-PAN H7N9 Formulation 3, AS03B, AS03A, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
833 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
8
States / cities
Stockbridge, Georgia • Meridian, Idaho • Cary, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Jun 10, 2026, 3:28 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluation of Adhesion and Dermal Tolerability of EMSAM

NCT00531596
View directory record Official record
Conditions
Healthy
Interventions
EMSAM (Selegiline Transdermal System) 6mg/24Hr, EMSAM (Selegiline Transdermal System) 9mg/24Hr, EMSAM (Selegiline Transdermal System) 12mg/24hr
Drug
Lead sponsor
Somerset Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
2
States / cities
Scottsdale, Arizona • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2007 · Synced Jun 10, 2026, 3:28 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults

NCT00192192
View directory record Official record
Conditions
Influenza
Interventions
CAIV-T
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000
U.S. locations
1
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 12, 2021 · Synced Jun 10, 2026, 3:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

NCT03694392
View directory record Official record
Conditions
Influenza, Pneumonia, Lower Respiratory Tract Infection, Acute Myocardial Infarction, Congestive Heart Failure, Stroke
Interventions
Flublok Quadrivalent, Standard Dose Inactivated Influenza Vaccine (SD-IIV)
Biological
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 64 Years
Enrollment
2,776,278 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Jun 10, 2026, 3:28 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

NCT03301051
View directory record Official record
Conditions
Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections, Influenza
Interventions
Quadrivalent VLP Vaccine, Placebo
Biological
Lead sponsor
Medicago
Industry
Eligibility
18 Years to 64 Years
Enrollment
10,160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
29
States / cities
Mobile, Alabama • Anaheim, California • Milford, Connecticut + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jun 10, 2026, 3:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults

NCT01416571
View directory record Official record
Conditions
Influenza
Interventions
Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Jun 10, 2026, 3:28 AM EDT
Completed No phase listed Observational

Clarksdale Diabetes and Metabolism Clinic CHEC Study

NCT00791453
View directory record Official record
Conditions
Diabetes
Interventions
Education
Behavioral
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated May 11, 2009 · Synced Jun 10, 2026, 3:28 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age

NCT06702449
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Candidate UTI vaccine low dose formulation 1, Candidate UTI vaccine low dose formulation 2, Candidate UTI vaccine medium dose formulation 1, Candidate UTI vaccine medium dose formulation 2, Candidate UTI vaccine high dose formulation 1, Candidate UTI vaccine high dose formulation 2, Candidate UTI vaccine HTD formulation 2, Placebo
Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
448 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
6
States / cities
Lenexa, Kansas • Secaucus, New Jersey • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jun 10, 2026, 3:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years

NCT00771615
View directory record Official record
Conditions
Influenza
Interventions
GSK A/turkey H5N1 Influenza vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
469 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
7
States / cities
Huntsville, Alabama • Anaheim, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Jun 10, 2026, 3:28 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years

NCT01712984
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation, Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
3,360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
38
States / cities
Hoover, Alabama • Huntsville, Alabama • Chandler, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Jun 10, 2026, 3:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age

NCT01999842
View directory record Official record
Conditions
Influenza
Interventions
Investigational H7N9 vaccine GSK3206641A, Investigational H7N9 vaccine GSK3206640A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
424 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
5
States / cities
Jacksonville, Florida • Stockbridge, Georgia • Boise, Idaho + 2 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jun 10, 2026, 3:28 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)

NCT05696080
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
V116, Placebo, PCV15, PPSV23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
518 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
8
States / cities
Mesa, Arizona • Hialeah, Florida • West Palm Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jun 10, 2026, 3:28 AM EDT
Terminated Phase 2 Interventional

A Pilot Study of Metabolic Effects of Omentectomy

NCT00565799
View directory record Official record
Conditions
Patients Who Consented to Undergo Laparoscopic Gastric Banding Surgery for Weight Loss and Consent to Participate in This studyBMI ≥35 kg/m2, Confirmed Type 2 Diabetes Treated With Oral Agents and/or Only Diet Therapy, Age 18-64 Years
Interventions
Omentectomy, No intervention
Procedure · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 64 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Jun 10, 2026, 3:28 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Immunogenicity of Influenza Vaccinations

NCT06518577
View directory record Official record
Conditions
Influenza
Interventions
Flucelvax (ccIIV4), Flublok (RIV) or Fluzone (IIV)
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years to 64 Years
Enrollment
605 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
7
States / cities
Phoenix, Arizona • Tempe, Arizona • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Jun 10, 2026, 3:28 AM EDT